Table 2.

Linear regression models of association of changes in bone mineral density among patients treated by Romosozumab

Factor	β	95% Confidence interval		P value
% Change of BMD of the lumbar spine
P1NP at BL	0.439	0.029	0.134	0.003
TRACP-5b at BL	0.576	0.010	0.029	< 0.001
% Change of P1NP at 3 M	− 0.136	− 0.033	0.014	0.422
% Change of TRACP-5b at 3 M	− 0.528	− 0.213	− 0.047	0.003
% Change of BMD of the femoral neck
P1NP at BL	0.343	0.001	0.209	0.049
TRACP-5b at BL	0.467	0.006	0.048	0.015
% Change of P1NP at 3 M	0.090	− 0.030	0.050	0.621
% Change of TRACP-5b at 3 M	− 0.160	− 0.216	0.093	0.424
% Change of BMD of the total hip
P1NP at BL	0.434	0.029	0.139	0.003
TRACP-5b at BL	0.329	0.008	0.024	0.037
% Change of P1NP at 3 M	− 0.079	− 0.030	0.019	0.659
% Change of TRACP-5b at 3 M	− 0.407	− 0.190	− 0.011	0.029

Adjusted by age, body mass index, pretreatment with BPs and active vitamin D, history of fragility fractures, and 25(OH)D levels

P1NP total type 1 procollagen-N-propeptide, TRACP-5b tartrate-resistant acid phosphatase 5b, 25(OH)D 25-hydroxy vitamin D, BL baseline, 3 M 3 months